Mayday University Hospital awarded 3 stars in NHS performance rating

Posted:
4
August 2005

Unit At Mayday

We are delighted to announce that Mayday University Hospital NHS Trust was recently issued an annual performance rating of 3 stars, which places them in the top 28% of Trusts in the UK. This is the highest rating available under the Healthcare Commission rating scheme.The performance rating reports are designed to review the key factors the Trusts need to achieve to deliver a better service to patients. This includes Patient Focus, Clinical Focus, Capacity and Capability Focus, Access to Quality Services, Improving Health and Services Provision. Overall, the Healthcare Commission report concluded that Mayday Hospital is delivering in each of these areas.Dr Jörg Täubel, Managing Director of Richmond Pharmacology, commented: “We have been working closely with the Trust over the past 18 months to facilitate the move of our second unit to Mayday hospital. Throughout this period of time I have been consistently impressed with the quality I experienced when working with the Trust. I am very pleased that this standard has been recognized by the Healthcare Commission. It's reassuring to conduct our trials within such a well managed, acute setting.”Richmond opened the new unit within Mayday University Hospital in May 2005.To view the Healthcare Commission report on Mayday click here.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more